Commercial Development

Brainalyze is advancing DementiaDX through larger-scale validation, strategic partnerships, and international commercialization initiatives.
As the company progresses toward regulatory and commercial scaling, we are actively engaging with pharmaceutical partners, healthcare organisations, diagnostics providers, and specialist MedTech and DeepTech investors aligned with the future of neurodegenerative disease diagnostics.

Our current strategic priorities include:

• Expanding multi-site clinical validation

• Supporting future trial stratification applications

• Developing scalable deployment pathways

• Advancing regulatory and commercialization planning

• Establishing manufacturing and distribution partnerships

With an initial focus on the United States market, Brainalyze is seeking collaborators and investment partners capable of supporting the next phase of platform development and global expansion.